🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🆕SUMMIT, 731👥IMC>=30,FEVi>=50%. 54%👩. 2años ✅Tirzepatide Vs Placebo 🔝💉Tirze: ✅⬇️38% Descompensación IC y ☠️CV. ✅⬆️KCCQ-CSS ✅⬇️Descompensaciones IC 46% ✅⬇️11.6% peso y 34.9PCRUS ✅🟰AES 👇🏼👇🏼 www-nejm-org.bvgcsalud.a17.csinet.es/doi/pdf/10.105… GT-SEMI Diabetes, Obesidad y Nutrición #17DM_SEMI @ICyFA-SEMI Juani Carretero Gomez José Pérez Silvestre

3️⃣ Long-Term Cumulative LDL-C Exposure and ASCVD Events in Young Adults with CAC=0: Insights from the CARDIA Study ahajournals.org/doi/abs/10.116…

Resistant hypertension was found associated with increased mortality only in those with increased 24-hour blood pressure. No differences were found between white-coat resistant hypertension and controlled hypertension Natalie Staplin Manuel Gorostidi ahajrnls.org/3ZiZnX5

MariTide (maridebart cafraglutide) Phase 2 Top-line Results Over 52 Weeks 🔹HbA1c: -2.2% (paired with -17% total body weight loss in T2D patients) 🔹TBWL: Exceeds 20% (in Obesity with no plateau) No new safety concerns were observed, and GI side effects showed rapid

"Does lowering LDL-C to very low levels result in long-term cognitive impairment?" 🧠🫀 I've heard this question many times. Now we have long-term data. A 🧵 on our new NEJM Evidence paper: evidence.nejm.org/doi/full/10.10… TIMI Study Group Robert Giugliano Michelle O'Donoghue

If I had elevated Lp(a), pending potential new therapies, I would be on a PCSK9i + statin (low dose) + ezetimibe. Since patients have high Lp(a) since birth the mantra needs to be "lower (very much) for longer" is better. It is no longer arguable. In such patients I desire LDL-C

🆓Revisión en NEJM sobre IC-FEp ‼️ 📌Repaso a toda la evidencia‼️ 👇🏼👇🏼👇🏼 nejm.org/doi/pdf/10.105… @ICyFA-SEMI José Pérez Silvestre Francesc Formiga🐜 Jesus Casado Marta Sánchez Alvaro Glez Franco Juan Carlos Obaya Joan Carles Trullàs, MD, PhD Emilio Sánchez Jaime Mazón GT-SEMI Diabetes, Obesidad y Nutrición #17DM_SEMI Sociedad Argentina de Medicina (SAM) Sociedad Española de Medicina Interna (SEMI)

🆕 Algoritmo del grupo de DM 2025!!! GT-SEMI Diabetes, Obesidad y Nutrición #17DM_SEMI ✅Situaciones clínicas ( 🆕MASLD/MASH) ✅HbA1c. ✅Explicación de cada situación clínica 👇🏼👇🏼👇🏼👇🏼 fesemi.org/sites/default/… Juani Carretero Gomez Javier Carrasco, PhD Juan Gonzalez Soler pablomiramontes Emilio Sánchez Marcos Gamboa Jaime Mazón

Novartis Amgen 🧪🔬🧬 Eli Lilly and Company Prof Kausik Ray FMedSci What are some estimates right now for answers to below? These estimates clearly impact the power of a given CVOT to "hit" how much Lp(a) lowering do you need over how long to lower CV risk a given amount? 1. magnitude of Lp(a) lowering required: based largely on human

And yet the most frequent etiological diagnosis of CKD... 🙈🙈 "imprecision medicine"

Great talk, Lale Tokgozoglu! 🧿🌷🙏 Her key message is one we should never forget: Middle age is already too late to take action on LDL lowering European Atherosclerosis Society

Lasix is NOT nephrotoxic 🫘 Please retweet so we can end this myth once and for all 🦄 Rising creatinine is more often an indicator of inadequate Lasix dosing than excessive!! Lasix can only harm the kidneys if it decreases cardiac output by dropping preload to the point of

Hospitalist and Resuscitationist 2025 (#HR25) conference blended cutting edge physiology, new evidence, and a ton of expert wisdom. It was incredible. Here were 10 of my top learnings 👇

Simultaneous initiation of finerenone + SGLT2i provides early and additive effects on UACR reduction, statistically and clinically significant. Symptomatic hypotension, AKI, and hyperK+ were uncommon. #CONFIDENCE #era2025 nejm.org/doi/full/10.10…

#HR25 was a blast! While it's not quite the experience as being there, for those who missed it, the lectures can be found here: vimeo.com/ondemand/hr25

¿Qué tienes que conocer de lo presentado en el Congreso de la ERA? #TakeHomeMessages ▶️SAVE THE DATE! 25 junio, 17h CEST Webinar: Lo + destacado de la ERA de la mano de 5 nefrólogos expertos en distintas áreas JovSEN Jaime Mazón | Moderación de Clara García Carro y Anna Buxeda

#ADA2025: STEP UP with Semaglutide 7.2 mg 💉 Higher dose, same weekly jab – does it shift the dial? 📊 74% completed 72-week tx • Mean WL: 🔹 Sema 7.2: −18.7% 🔹 Sema 2.4: −15.6% 🔹 Placebo: −3.9% 📉 ≥20% WL: 🔹 21.6% (7.2) vs 13.5% (2.4) vs 2.2% (pbo) 🎯 Waist ↓: p<0.001

Original Article: Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2 phase 3a trial) nej.md/4ehQwLk American Diabetes Association - DiabetesPro | #ADASciSessions

📢Seminario web ADA Highlights 2025 - 85º Meeting of American Diabetes Association del GT GT-SEMI Diabetes, Obesidad y Nutrición #17DM_SEMI de Sociedad Española de Medicina Interna (SEMI) 🏥🩺 🗓️Miércoles, 16 de julio | 18:00 – 19:15 HORAS 🔹Inscripción gratuita intranet.pacifico-meetings.com/GescoWeb/?cfg=… 🔹Plataforma de acceso al seminario

🚨 Finerenone Approved by US FDA in HF based on #FINEARTSHF Finerenone (Kerendia) is a non-steroidal MRA indicated to reduce the risk of CV death, hospitalization for HF, & urgent HF visits in adult patients with HF with LVEF>= 40% bayer.com/media/en-us/us…